Effect of the RESPECT Trial on Lipid-lowering Treatment Adherence

This is a pilot-study of the Role of Screening With Coronary Computed Tomography Angiography in Primary Prevention of Coronary Heart Disease (RESPECT [NCT05431309]) trial.The primary objective of this study is to determine whether coronary computed tomography angiography (CCTA) -based coronary heart disease(CHD) prevention strategy improves lipid-lowering treatment adherence and risk factor control compared with traditional CHD prevention strategy, guided by a cardiovascular risk score.

Inclusion Criteria:1.Resident population aged 40-69 in Nanjing, ChinaExclusion Criteria:1.Plan to leave Nanjing within 5 years or be unable to complete the follow-up work2.Refuse to sign informed consent3.Known atherosclerotic cardiovascular disease (eg. angina, coronary heart disease, stroke, transient ischemic attack, peripheral vascular disease)4.Serious chronic kidney disease (eGFR< 30 ml/min/1.73 m2)5.Serious liver disease or dysfunction (chronic active hepatitis and cirrhosis, or aspartate aminotransferase (AST) or alanine transaminase (ALT) > 3 times the upper limit of normal)6.Prior coronary computed tomography angiography or invasive coronary angiography within the last 5 years7.Not appropriate to be tested due to birth planning, allergies, acute thyroid storm, etc8.Current use of lipid-lowering treatment (including statin and nonstatin drugs, such as ezetimibe, PCSK9 inhibitor, Xuezhikang,etc)9.Patients with diseases that seriously affect the survival period, such as malignant tumors10.Other conditions at the discretion of the research group